Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions (Q33425421)

26 July 2017

title

Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions (English)

1 reference

26 July 2017

0 references

1

Diana Karpman

1 reference

26 July 2017

Anne-lie Ståhl

2

1 reference

26 July 2017

Ida Arvidsson

3

1 reference

26 July 2017

Karl Johansson

4

1 reference

26 July 2017

Sebastian Loos

5

1 reference

26 July 2017

Ramesh Tati

6

1 reference

26 July 2017

Zivile Békássy

7

1 reference

26 July 2017

Ann-Charlotte Kristoffersson

8

1 reference

26 July 2017

Maria Mossberg

9

1 reference

26 July 2017

Robin Kahn

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Advances in Experimental Medicine and Biology

26 July 2017

published in

1 reference

26 July 2017

volume

865

1 reference

26 July 2017

page(s)

19-42

1 reference

Complement. First of two parts

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Receptors, rafts, and microvesicles in thrombosis and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement and complement regulatory proteins as potential molecular targets for vascular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The contact/kinin and complement systems in vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cross-talk between the complement and the kinin system in vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement-mediated regulation of tissue factor activity in endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cellular mechanisms underlying the formation of circulating microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Ectocytosis caused by sublytic autologous complement attack on human neutrophils. The sorting of endogenous plasma-membrane proteins and lipids into shed vesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial activation and circulating markers of endothelial activation in kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microvesicles and viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microparticles: protagonists of a novel communication network for intercellular information exchange

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Leukocyte-derived microparticles in vascular homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Red blood cell microparticles: clinical relevance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles in diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Highlights of a new type of intercellular communication: microvesicle-based information transfer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Modulation of monocyte-endothelial cell interactions by platelet microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The many faces of endothelial microparticles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Regulation of transbilayer plasma membrane phospholipid asymmetry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microparticles in hemostasis and thrombosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Role of microparticles in atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microthrombocytosis and Platelet Fragmentation Associated with Idiopathic/Autoimmune Thrombocytopenic Purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial and platelet microparticles in vasculitis of the young.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Specific Interaction of Escherichia coli 0157:H7-Derived Shiga-like Toxin II with Human Renal Endothelial Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet activation in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Experimental studies on the hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Hemolytic uremic syndrome in children: platelet aggregation and membrane glycoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet activation leads to activation and propagation of the complement system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Studies on the binding of complement factor C4 in human platelets. Complement activation by means of cold agglutinins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Activation of human platelets through gp140, the C3d/EBV receptor (CR2)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human platelet-initiated formation and uptake of the C5-9 complex of human complement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human platelet activation by C3a and C3a des-arg

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Identification of a third component of complement-binding glycoprotein of human platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Factor H binds to washed human platelets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Platelet-associated complement factor H in healthy persons and patients with atypical HUS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Association of alternative complement pathway components with human blood platelets: secretion and localization of factor D and beta 1H Globulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement and the atypical hemolytic uremic syndrome in children.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement factor H related proteins in immune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The development of atypical hemolytic uremic syndrome depends on complement C5

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation in thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombotic Thrombocytopenic Purpura with C′3Vascular Deposits: Report of a Case

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The interaction between factor H and Von Willebrand factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Human complement factor H is a reductase for large soluble von Willebrand factor multimers--brief report

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Endothelial microparticles and the diagnosis of the vasculitides

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Diagnostic role of endothelial microparticles in vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab in severe Shiga-toxin-associated HUS

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

Progress and Trends in Complement Therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-18603-0_2

10.1007/978-3-319-18603-0_2

31 March 2020

Identifiers

DOI

1 reference

26 July 2017

1 reference